公开(公告)号：US20230279351A1

公开(公告)日：2023-09-07

申请号：US17596493

申请日：2020-06-24

申请人： Seattle Children's Hospital (dba Seattle Children's Research Institute) ,  Benaroya Research Institute at Virginia Mason

发明人： Jane Buckner ,  David J. Rawlings ,  Karen Sommer ,  Yuchi Chiang Honaker ,  Peter Cook ,  Akhilesh Kumar Singh ,  Soo Jung Yang

IPC分类号： C12N5/0783 ,  C07K14/47 ,  C07K14/725

CPC分类号： C12N5/0637 ,  C07K14/4702 ,  C07K14/7051 ,  C12N2310/20 ,  C12N2510/00

摘要： Some embodiments of the compositions and methods disclosed herein include gene-edited, artificial immunoregulatory T cells (airT cells) comprising a constitutively expressed FoxP3 gene product expressed at a level equal to or greater than the level of FoxP3 expression in natural T regulatory (Treg or suppressor T) cells, and a transduced (e.g., artificially engineered by gene editing, viral vector transduction, transfection or other genetic engineering methodologies) T cell receptor (TCR). In some embodiments, the TCR is preferably specific for an antigen associated with an autoimmune, allergic, or other inflammatory condition. Some embodiments include methods for the preparation and/or use of airT cells. Some such embodiments include use of airT cells for the treatment and/or amelioration of a disorder, in which antigen-specific immunosuppression may be beneficial, such as an autoimmune, allergic, or other inflammatory disorder.